T Cells: Ready and waiting to go
Some T cells that have been activated by a herpesvirus can also respond to SARS-CoV-2, even if the original herpesvirus infection happened before the COVID-19 pandemic.
- School of Cellular and Molecular Medicine, Faculty of Life Sciences, University of Bristol, United Kingdom
- Bristol Veterinary School, Faculty of Health Sciences, University of Bristol, United Kingdom
Cells called T cells play an important role in protecting the body against infection by removing pathogens that may cause harm. Two major types of T cell are involved in the response to a viral infection. Both become activated when their receptors recognize short peptides from viral proteins called ‘epitopes’: CD8 T cells directly attack infected cells, whereas CD4 T cells help other immune cells (called B cells) to produce antibodies. Once the infection has been eliminated, some of these CD8 and CD4 T cells survive in the body as long-lived memory T cells which can immediately respond if the virus invades again.
Previous studies found that some blood samples taken before the COVID-19 pandemic already contained T cells that could recognize the SARS-CoV-2 virus (Grifoni et al., 2020; Le Bert et al., 2020). However, researchers still do not fully understand how these T cells arose, or how they impact immunity and disease outcomes for COVID-19 patients.
One possibility is that these pre-existing T cells arose due to a phenomenon called heterologous immunity (Welsh et al., 2010). This is when CD4 and CD8 T cells activated by a specific pathogen ‘cross-react’ and respond to epitopes from a different virus (Mason, 1998). It was previously thought that coronaviruses already circulating in the population before the pandemic were responsible for the existence of some T cells that could recognise SARS-CoV-2 (Grifoni et al., 2020; Swadling et al., 2022). Now, in eLife, Cilia Pothast (Leiden University Medical Center), Mirjam Heemskerk (also at Leiden) and colleagues report that another group of viruses may have also been involved (Pothast et al., 2022).
The team hypothesised that some of the T cells specific to SARS-CoV-2 had been activated by a herpesvirus called human cytomegalovirus (HCMV). This pathogen is highly prevalent in the population and has also been linked to changes in the severity of COVID-19 symptoms (Alanio et al., 2022). To investigate, they stimulated pre-pandemic blood samples with different segments of SARS-CoV-2 proteins. This led them to discover a population of ‘cross-reactive’ CD4 and CD8 T cells that can recognize epitopes from both SARS-CoV-2 and HCMV (Figure 1).
Figure 1
Infection with human cytomegalovirus (HCMV) can stimulate T cells that can recognise SARS-CoV-2.
When individuals are infected with HCMV (virus shown in pink), the population of T cells that can detect this virus expands (T cells shown here in purple). Cross-reactivity is a well-known feature of the immune response. Through this process, HCMV infection can activate T cells (shown here in green) that can recognise both HCMV and another pathogen – including the SARS-CoV-2 virus, even if the HCMV infection happened before the COVID-19 pandemic. These cross-reactive T cells may be able to contribute to the immunity of an individual to SARS-CoV-2, as well as to how COVID-19 affects their body.
Image credit: Created with BioRender.com.
Pothast et al. found that this cross-reactivity was due to a T cell receptor that is expressed in multiple individuals. However, there are very few similarities between the amino acid sequences of the SARS-CoV-2 and the HCMV epitopes, bringing into question how this T cell receptor can detect both viruses. It may be possible to explain the molecular basis for this observation by solving crystal structures of this T cell receptor in complex with either the presented HCMV or SARS-CoV-2 epitopes.
Further experiments then revealed that the cross-reactive T cells limit the replication of SARS-CoV-2 in vitro when the virus is present at low levels. However, the cross-reactive T cells did not appear to have an activated phenotype in patients with severe COVID-19. This might be because individuals included in this study were over 60 years of age, and HCMV-specific T cells do not work as well as people get older (Ouyang et al., 2004).
It has been suggested that heterologous immunity may play a beneficial role in protective immunity (Welsh et al., 2010). This is consistent with a recent study showing that T cells which cross-react with SARS-CoV-2 are associated with abortive infections (when the virus fails to spread to other cells) and asymptomatic cases of COVID-19 (Swadling et al., 2022). These pre-existing T cells may also enhance a person’s response to vaccines (Loyal et al., 2021). However, heterologous immunity is a double-edged sword, as it can also increase the severity of some viral infections. For example, in dengue infections, cross-reactive antibodies and T cells can result in an immune response that is harmful to the body (Welsh et al., 2010; Screaton et al., 2015).
Further studies are needed to establish whether other pathogens (including bacteria) can stimulate T cells capable of recognising epitopes from SARS-CoV-2. In addition, studies with larger cohorts of vaccinated individuals and patients with mild or severe COVID-19 are required to define the role that these cross-reactive T cells play in protective immunity, in response to vaccination, and in disease pathology.
References
-
Cytomegalovirus latent infection is associated with an increased risk of COVID-19-related hospitalizationThe Journal of Infectious Diseases 226:463–473.https://doi.org/10.1093/infdis/jiac020
-
Dysfunctional CMV-specific CD8(+) T cells accumulate in the elderlyExperimental Gerontology 39:607–613.https://doi.org/10.1016/j.exger.2003.11.016
-
New insights into the immunopathology and control of dengue virus infectionNature Reviews Immunology 15:745–759.https://doi.org/10.1038/nri3916
-
Heterologous immunity between virusesImmunological Reviews 235:244–266.https://doi.org/10.1111/j.0105-2896.2010.00897.x
Article and author information
Author details
Publication history
Copyright
© 2023, Rivino and Wooldridge
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 872
- views
-
- 73
- downloads
-
- 1
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
T Cells: Ready and waiting to go
eLife 12:e85080.
https://doi.org/10.7554/eLife.85080
Further reading
-
- Immunology and Inflammation
Type 1 diabetes mellitus (T1DM), known as insulin-dependent diabetes mellitus, is characterized by persistent hyperglycemia resulting from damage to the pancreatic β cells and an absolute deficiency of insulin, leading to multi-organ involvement and a poor prognosis. The progression of T1DM is significantly influenced by oxidative stress and apoptosis. The natural compound eugenol (EUG) possesses anti-inflammatory, anti-oxidant, and anti-apoptotic properties. However, the potential effects of EUG on T1DM had not been investigated. In this study, we established the streptozotocin (STZ)-induced T1DM mouse model in vivo and STZ-induced pancreatic β cell MIN6 cell model in vitro to investigate the protective effects of EUG on T1DM, and tried to elucidate its potential mechanism. Our findings demonstrated that the intervention of EUG could effectively induce the activation of nuclear factor E2-related factor 2 (NRF2), leading to an up-regulation in the expressions of downstream proteins NQO1 and HMOX1, which are regulated by NRF2. Moreover, this intervention exhibited a significant amelioration in pancreatic β cell damage associated with T1DM, accompanied by an elevation in insulin secretion and a reduction in the expression levels of apoptosis and oxidative stress-related markers. Furthermore, ML385, an NRF2 inhibitor, reversed these effects of EUG. The present study suggested that EUG exerted protective effects on pancreatic β cells in T1DM by attenuating apoptosis and oxidative stress through the activation of the NRF2 signaling pathway. Consequently, EUG holds great promise as a potential therapeutic candidate for T1DM.
-
- Computational and Systems Biology
- Immunology and Inflammation
Transcription factor partners can cooperatively bind to DNA composite elements to augment gene transcription. Here, we report a novel protein-DNA binding screening pipeline, termed Spacing Preference Identification of Composite Elements (SPICE), that can systematically predict protein binding partners and DNA motif spacing preferences. Using SPICE, we successfully identified known composite elements, such as AP1-IRF composite elements (AICEs) and STAT5 tetramers, and also uncovered several novel binding partners, including JUN-IKZF1 composite elements. One such novel interaction was identified at CNS9, an upstream conserved noncoding region in the human IL10 gene, which harbors a non-canonical IKZF1 binding site. We confirmed the cooperative binding of JUN and IKZF1 and showed that the activity of an IL10-luciferase reporter construct in primary B and T cells depended on both this site and the AP1 binding site within this composite element. Overall, our findings reveal an unappreciated global association of IKZF1 and AP1 and establish SPICE as a valuable new pipeline for predicting novel transcription binding complexes.
